Navigation Links
McLean Report on nanotechnology that may enhance medication delivery and improve MRI performance
Date:5/1/2012

Belmont, MA - Researchers at Harvard-affiliated McLean Hospital have shown a new category of "green" nanoparticles comprised of a non-toxic, protein-based nanotechnology that can non-invasively cross the blood brain barrier and is capable of transporting various types of drugs.

In an article published May 1, 2012 online in PLoS ONE, Gordana Vitaliano, MD, director of the Brain Imaging NaNoTechnology Group at the McLean Hospital Imaging Center, reported that clathrin protein, a ubiquitous protein found in human, animal, plant, bacteria and fungi cells, can been modified for use as a nanoparticle for in-vivo studies. "Clathrin has never been modified for use in vivo and offers many new and interesting possibilities for delivering drugs and medical imaging agents into the brain", said Vitaliano.

Clathrin is the body's primary delivery vehicle responsible for delivering many different types of molecules into cells. Vitaliano therefore believed that the protein's naturally potent transport capabilities might be put to practical medical use for drug delivery and medical imaging.

"This study provides a new insight into utilizing bioengineered clathrin protein as a novel nanoplatform that passes the blood brain barrier," said Vitaliano, who successfully attached different fluorescent labels, commonly used in imaging, to functionalize clathrin nanoparticles. "We were able to show that the clathrin nanoparticles could be non-invasively delivered to the central nervous system (CNS) in animals. The clathrin performed significantly."

Of major importance for future clinical applications, Vitaliano also showed that clathrin crossed and/or bypassed the blood-brain barrier without enhancers or modifications, unlike other nanoparticles. These findings open the door to exploring new and important CNS medical applications.

One important medical application for clathrin nanoparticles would be Magnetic Resonance Imaging (MRI). Gadolinium contrast agents are often used to improve MRI performance. In one configuration, Vitaliano found that functionalized clathrin nanoparticles performed 8,000 times better than an FDA approved MRI contrast agent (gadopentetate dimeglumine).

"Stated another way, it means 8,000 times less gadolinium might be required for achieving good MRI results. Because very low gadolinium concentrations would be required for MRI, it could significantly decrease gadolinium toxicity, which is an important issue," explained Vitaliano. "Clathrin transported gadolinium is therefore among the most potent, biocompatible contrast agents available."

These results in two different applications showed that clathrin offers substantial functionalization and transport flexibility. Purified clathrin nanoparticles could therefore serve as an appealing alternative to other medical nanoplatforms such as dendrimers, nanogels, solid lipid nanospheres, liposomes, and the like.

Given the critical need for new types of CNS drug transport capabilities, Vitaliano said her work would likely be of interest to researchers involved in neuroimaging and neuroscience, but also to radiologists, bioengineers, chemists, physicists, material scientists, biomedical researchers, and other researchers active at the frontiers of imaging and drug delivery.

Looking ahead, Vitaliano noted that her findings may also facilitate other studies for examining signaling pathways in different diseases that rely in whole or in part on clathrin transport, and thus may have a substantial impact in multiple fields.


'/>"/>

Contact: Adriana Bobinchock
abobinchock@partners.org
617-855-2110
McLean Hospital
Source:Eurekalert

Related biology technology :

1. Innophos Holdings, Inc. Reports First Quarter 2012 Results
2. 3SBio Inc. Files Annual Report on Form 20-F for Fiscal Year 2011
3. Cell Therapeutics, Inc. (CTI) Reports First Quarter Financial Results and Milestones
4. Cryo-Cell Reports Financial Results for First Quarter 2012
5. Vermillion Reports Fourth Quarter and Full Year 2011 Results
6. Soligenix Reports Year-End 2011 Financial Results and Highlights Recent Accomplishments
7. Xention Reports Positive Phase 1 Data for New Atrial Fibrillation Drug
8. GenVec Reports Fourth Quarter and 2011 Year-End Financial Results
9. Pharma IQs Compound Management Survey Report
10. EntreMed Reports Fourth Quarter and Year-End 2011 Financial Results
11. Phalanx Biotech Group Reports Robust Revenue Growth in 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... , June 27, 2016  Global demand ... 4.6 percent through 2020 to $7.2 billion.  This ... and beverages, cleaning products, biofuel production, animal feed, ... biotechnology, diagnostics, and biocatalysts). Food and beverages will ... driven by increasing consumption of products containing enzymes ...
(Date:6/27/2016)... ... 2016 , ... Parallel 6 , the leading software as a service ... Virtual Patient Encounter CONSULT module which enables both audio and video telemedicine communication ... , Using the CONSULT module, patients and physicians can schedule a face to face ...
(Date:6/27/2016)...   Ginkgo Bioworks , a leading organism ... today awarded as one of the World Economic ... most innovative companies. Ginkgo Bioworks is engineering biology ... world in the nutrition, health and consumer goods ... customers including Fortune 500 companies to design microbes ...
(Date:6/24/2016)... ... ... Researchers at the Universita Politecnica delle Marche in Ancona combed medical journal articles ... findings are the subject of a new article on the Surviving Mesothelioma website. ... blood, lung fluid or tissue of mesothelioma patients that can help point doctors to ...
Breaking Biology Technology:
(Date:5/20/2016)... , May 20, 2016  VoiceIt is ... partnership with VoicePass. By working together, ... experience.  Because VoiceIt and VoicePass take slightly different ... engines increases both security and usability. ... excitement about this new partnership. "This ...
(Date:5/9/2016)... -- Elevay is currently known as the ... high net worth professionals seeking travel for work   ... there is still no substitute for a face-to-face meeting. ... deal with a firm handshake. This is why wealthy ... citizenship via investment programs like those offered by the ...
(Date:4/28/2016)... First quarter 2016:   , Revenues amounted ... quarter of 2015 The gross margin was 49% (27) ... the operating margin was 40% (-13) Earnings per share ... operations was SEK 249.9 M (21.2) , Outlook   ... M. The operating margin for 2016 is estimated to ...
Breaking Biology News(10 mins):